PD-1/PD-L1 checkpoint blockade has been shown to promote anti-tumor immunity by reducing CTLs depletion, especially when combined with other treatment regimens, the anti-tumor effect can be significantly improved [43]. Here, PDCD1 is linked to neoplasm.